Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10mg+ metformin SR 500mg in diabetic dyslipidaemia in adult Indian patients

Journal of the Indian Medical Association

Volumn 106, Issue 7, 2008, Pages 464-467

  Balasubramanian, R ^a   Varadharajan, S ^b   Kathale, Ashish ^c   Nagraj, L M ^d   Periyandavar, I ^e   Nayak, Uday P ^f   Sharma, Akhilesh ^g   Bolmall, Chandrashekhar ^g   Baliga, Vidyagauri P ^g  

^a Sri Manakula Vinayagar Medical College and Hospital ^*  (India)

^b Raajah Hospitals   (India)

^c Gurde Hospital   (India)

^d Prakash Clinic   (India)

^e Lifeline Diabetes Centre   (India)

^f Nayak Medicare   (India)

^g Glenmark Pharmaceuticals Limited   (India)

Author keywords

Atorvastatin; Diabetes; Dyslipidaemia; Metformin

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; ATORVASTATIN PLUS METFORMIN; CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; CORONARY RISK; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHASE 3 CLINICAL TRIAL; SUSTAINED RELEASE PREPARATION; DRUG COMBINATION; GLYCEMIC INDEX; INDIA; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; GLYCEMIC INDEX; HEPTANOIC ACIDS; HUMANS; HYPOGLYCEMIC AGENTS; INDIA; MALE; METFORMIN; MIDDLE AGED; PYRROLES;

EID: 58149173863     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Almdal T, Scharling H, Jensen JS, Vestergaard H - The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death. Arch Intern Med 2004; 164: 1422-6.
2. Ho JE, Paultre F, Mosca L - Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the Women's Pooling Project. Stroke 2003; 34: 2812-6.
3. Stamler J, Vaccaro O, Neaton JD, Wenlworth D - Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-44.
4. Kannel WB, McGee DL - Diabetes and cardiovascular disease: the Framingham Study. JAMA 1979; 241: 2035-8.
5. Heart Protection Study Collaborative Group - MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
6. Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, et al - Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 1998; 98: 2513-9.
7. PyoräJä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG. Thorgeirsson G - Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-20.
8. Athyros VG Papageorgiou AA, Symeonidis AN, Didangelos TP, Pehlivanidis AN, Bouloukos VI, et al - Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus: a subgroup analysis of the GREEK Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Angiology 2003; 54: 679-90.
9. Kirpichnikov D, McFarlane SI, Sowers JR - Metformin: an Update. Ann Intern Med 2002; 137: 25-33.
10. Best JD, O'Neal DN - Diabetic dyslipidaemia: current treatment recommendations. Drugs 2000; 59: 1101-11.
11. Diabetes Atorvastatin Lipid Intervention (DALI) Study Group - The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001; 24: 1335-41.
12. 2 Aguilar-Salinas CA, Gómez-Pérez FJ, Posadas-Romero C, Vázquez-Chávez C, Meaney E, Gulías-Herrero A, et al - Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients: a 34-week, multicenter, open-label study. Atherosclerosis 2000; 152: 489-96.
13. 3 Croom KF, Plosker GL - Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. Drugs 2005; 65: 137-52.
14. Cusi K, DeFronzo RA - Metformin: a review of its metabolic effect. Diabetes Rev 1998; 6: 89-131.
15. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, et al - Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063-9.
16. Radziuk J, Zhang Z, Wiensperger N, Pye S - Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes 1997; 46: 1406-13.
17. Dailey GE - Contributions of fasting and post-prandial plasma glucose levels to glycosylaied hemoglobin and diabetes mellitus-related complications: treating hyperglycemia with insulin. Insulin 2006; 1: 148-57.
18. 8 Steiner G - Lipid intervention trials in diabetes. Diabetes Care 2000; 23: B49-53.
19. American Diabetes Association - Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21: 179-82.
20. Taskinen MR - Triglyceride is the major atherogenic lipid in NIDDM. Diabetes Metab Rev 1997; 13: 93-8.